News Sentiment

XGN sentiment intelligence

Exagen Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 4.45 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-2.0% over one week, -4.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

ETFs Investing in Exagen, Inc. Stocks

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -2.0% Price reacting lower
Trend fit Trend inactive -4.7% over four weeks
Fair value 6.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 32
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
TradingKey 7
Market source 6
Stock Titan 4
GuruFocus 2
MarketBeat 2
simplywall.st 2
AD HOC NEWS 1

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 17
Analyst action 8
Balance sheet 1
Regulatory and legal 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
TradingView Direct company coverage

ETFs Investing in Exagen, Inc. Stocks

This article identifies ETFs that hold stocks of Exagen, Inc. (E08A), a medical/nursing services company. It lists two specific ETFs, iShares Microcap ETF (IWC) and Invesco NASDAQ Future Gen 200 ETF (QQQS), detailing their market value, weight of Exagen stock, issuer, management

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 00:12
Source
TradingView
AD HOC NEWS Direct company coverage

Exagen Inc focuses on autoimmune diagnostics as investors watch strategy

Exagen Inc, a specialized diagnostics company, is capturing investor attention with its focus on autoimmune disease diagnostics, particularly systemic lupus erythematosus and rheumatoid arthritis. The company's strategy involves building a strong testing portfolio, securing comme

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 18:41
Source
AD HOC NEWS
Moomoo Direct company coverage

Exagen(XGN) Stock Options Chain | Quotes & News

This document appears to be a placeholder or an incomplete article about Exagen (XGN) stock options, quotes, and news. No actual content beyond the title is provided, making it impossible to extract further details.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 11:11
Source
Moomoo
Finviz Direct company coverage

XGN - Exagen Inc Volatility & Greeks

This article provides a detailed financial overview of Exagen Inc. (XGN), covering its recent stock performance, key financial metrics like market capitalization, income, sales, and various ratios. It also includes information on insider and institutional ownership, analyst recom

Tone
Negative 40/100
Event
Analyst action
Published
02 Jul 2026 21:09
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Exagen Inc. – NASDAQ:XGN

This page provides financial information for Exagen Inc. (NASDAQ: XGN) on TradingView, specifically focusing on its Price to Sales (forward) metric. The content confirms that the market was closed at the time of viewing, with no trades occurring.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 22:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Exagen Inc. – NASDAQ:XGN

The article focuses on the "Price to earnings forward" financial metric for Exagen Inc. (NASDAQ: XGN). It is presented within the context of TradingView's financial analysis tools, indicating that the data is provided by ICE Data Services and FactSet. The content is primarily a d

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 08:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Exagen, Inc. – LS:A2PRXT

This article provides financial information for Exagen, Inc. (A2PRXT) on TradingView, specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of viewing. The content appears to be a stub or an incomplete dat

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 06:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Exagen Inc. – NASDAQ:XGN

This article provides financial context for Exagen Inc. (NASDAQ: XGN), specifically focusing on its enterprise value to EBIT forward. It appears to be a financial snapshot or data point from TradingView, without additional analysis or narrative.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 17:39
Source
TradingView
TradingView Direct company coverage

A2PRXT Forecast — Price Target — Prediction for 2027

This article provides a forecast for Exagen, Inc. (A2PRXT) stock, including analyst price targets, past performance, and key financial data. According to analysts, the stock has a max estimate of 8.79 EUR and a min estimate of 7.03 EUR. The article also covers reported earnings,

Tone
Positive 60/100
Event
Analyst action
Published
29 Jun 2026 16:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Exagen Inc. – NASDAQ:XGN

The article focuses on the "Price to book forward" metric for Exagen Inc. (NASDAQ: XGN). It provides general financial and market information related to the company within the TradingView platform, without specific financial figures or detailed analysis. The content appears to be

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 03:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Exagen, Inc. – GETTEX:E08A

This article provides financial information for Exagen, Inc. (GETTEX:E08A), specifically focusing on its Enterprise Value to EBIT forward metric. The content highlights the company's financial data as part of its stock market listing on Gettex, indicating a focus on investor-rela

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 09:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Exagen Inc. – NASDAQ:XGN

This article displays the forward Enterprise Value to EBITDA for Exagen Inc. (NASDAQ: XGN) on TradingView. It provides financial data related to the company, indicating the market is currently closed with no trades. The information is presented on the TradingView platform, which

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 02:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Exagen Inc. – NASDAQ:XGN

The article provides financial information for Exagen Inc. (NASDAQ:XGN), specifically highlighting its enterprise value to revenue forward metric. This data is presented within the context of TradingView's platform, offering an overview of the company's financials for market anal

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 21:09
Source
TradingView
TradingView Direct company coverage

Exagen, Inc. Actuals & Estimates (NASDAQ:XGN)

This article provides key financial actuals, estimates, and analyst forecasts for Exagen Inc. (NASDAQ: XGN). It details recent stock performance, future price predictions, upcoming earnings dates, and current financial metrics like market capitalization, revenue, and EBITDA. The

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 20:40
Source
TradingView
TradingView Direct company coverage

XGN Forecast — Price Target — Prediction for 2027

This article provides an overview of Exagen Inc. (XGN) stock, including its current price, analyst forecasts, and various financial metrics. It highlights the company's price target of $8.57, with analysts predicting a maximum of $10.00 and a minimum of $8.00. The article also co

Tone
Positive 61/100
Event
Analyst action
Published
25 Jun 2026 17:40
Source
TradingView
GuruFocus Direct company coverage

XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rat

Roth Capital has initiated coverage on Exagen (XGN) with a Buy rating and a price target of $8.00. While analysts see potential upside, GuruFocus indicates the stock is currently 51.0% overvalued with a GF Value™ of $3.00, suggesting caution due to mixed financial metrics and mod

Tone
Positive 64/100
Event
Analyst action
Published
25 Jun 2026 12:11
Source
GuruFocus
Investing.com South Africa Direct company coverage

Form 4 Exagen Inc For: 24 June By Investing.com

This article reports on the filing of Form 4 for Exagen Inc. (XGN) on June 24th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article also provides curre

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 05:40
Source
Investing.com South Africa
GuruFocus Direct company coverage

Exagen (XGN) Gains Buy Rating with $8 Price Target from Analyst

Roth Capital has initiated coverage of Exagen (XGN) with a Buy rating and an $8 price target, driven by the strength of its autoimmune testing range, particularly the AVISE CTD test. Despite a moderate GF Score™ of 58 and concerns about financial strength and profitability, the c

Tone
Positive 66/100
Event
Analyst action
Published
25 Jun 2026 04:10
Source
GuruFocus
Investing.com Australia Direct company coverage

Form 4 Exagen Inc For: 22 June By Investing.com

This article announces the filing of Form 4 for Exagen Inc. on June 22. It is a brief financial news update from Investing.com reporting the regulatory filing related to insider transactions for the company.

Tone
Negative 42/100
Event
Regulatory and legal
Published
23 Jun 2026 03:11
Source
Investing.com Australia
Stock Titan Direct company coverage

Exagen (XGN) director granted 37,500 stock options at $4.31 strike

Exagen Inc. director Chas McKhann was granted 37,500 stock options at an exercise price of $4.31 per share. These options will vest fully on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided he continues his board service. Fol

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 17:11
Source
Stock Titan
Stock Titan Direct company coverage

Exagen (XGN) director Frank Stokes receives 37,500 stock options at $4.31

Exagen Inc. director Frank Stokes was granted 37,500 stock options at an exercise price of $4.31 per share. These options will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided he continues his board service. Following

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 17:11
Source
Stock Titan
Stock Titan Direct company coverage

Exagen (XGN) director Scott Kahn receives 37,500 stock options grant

Exagen (XGN) director Scott D. Kahn was granted 37,500 stock options with an exercise price of $4.31 per share, expiring on June 8, 2036. These options will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, provided Kahn re

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 17:11
Source
Stock Titan
TradingKey Direct company coverage

Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Exagen Inc (XGN), noting its current valuation score of 7.76, placing it 56th out of 76 in the Healthcare Providers & Services industry. The P/E ratio is reported as -5.10, with other key metrics like P/B, P/S, and P/CF not yet discl

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:39
Source
TradingKey
TradingKey Direct company coverage

Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Exagen Inc (XGN)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split history. The page also presents current stock performance data for XG

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:10
Source
TradingKey
TradingKey Direct company coverage

Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Exagen Inc (XGN), detailing its performance across various business segments. It shows that Commercial, Government, and Client segments are the primary contributors to the company's revenue, with specific proportions for each. The dat

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:10
Source
TradingKey
TradingKey Direct company coverage

Exagen Inc (XGN) Financial Health: Profitability & Balance Sheet Analysis

Exagen Inc (XGN) currently holds a financial score of 6.90, ranking 59 out of 76 in the Healthcare Providers & Services industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue saw an 11.67% year-over-year increase, with ne

Tone
Positive 58/100
Event
Earnings
Published
17 Jun 2026 14:40
Source
TradingKey